L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy
Top Cited Papers
- 24 August 2003
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 9 (9) , 1187-1194
- https://doi.org/10.1038/nm920
Abstract
Under conditions of iron overload, which are now reaching epidemic proportions worldwide, iron-overload cardiomyopathy is the most important prognostic factor in patient survival. We hypothesize that in iron-overload disorders, iron accumulation in the heart depends on ferrous iron (Fe2+) permeation through the L-type voltage-dependent Ca2+ channel (LVDCC), a promiscuous divalent cation transporter. Iron overload in mice was associated with increased mortality, systolic and diastolic dysfunction, bradycardia, hypotension, increased myocardial fibrosis and elevated oxidative stress. Treatment with LVDCC blockers (CCBs; amlodipine and verapamil) at therapeutic levels inhibited the LVDCC current in cardiomyocytes, attenuated myocardial iron accumulation and oxidative stress, improved survival, prevented hypotension and preserved heart structure and function. Consistent with the role of LVDCCs in myocardial iron uptake, iron-overloaded transgenic mice with cardiac-specific overexpression of the LVDCC α1-subunit had twofold higher myocardial iron and oxidative stress levels, as well as greater impairment in cardiac function, compared with littermate controls; LVDCC blockade was again protective. Our results indicate that cardiac LVDCCs are key transporters of iron into cardiomyocytes under iron-overloaded conditions, and potentially represent a new therapeutic target to reduce the cardiovascular burden from iron overload.Keywords
This publication has 62 references indexed in Scilit:
- Recent advances in disorders of iron metabolism: mutations, mechanisms and modifiersHuman Molecular Genetics, 2001
- Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemiasNature Reviews Genetics, 2001
- Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell diseaseSeminars in Hematology, 2001
- Disorders of Iron MetabolismNew England Journal of Medicine, 1999
- Growth, Puberty and Endocrine Function in Beta-Thalassaemia MajorJournal of Pediatric Endocrinology and Metabolism, 1997
- Thalassemia — a global public health problemNature Medicine, 1996
- Hemochromatosis: The genetic disorder of the twenty–first centuryNature Medicine, 1996
- Survival in Medically Treated Patients with Homozygous β-ThalassemiaNew England Journal of Medicine, 1994
- SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJORPublished by Elsevier ,1989
- Iron in the heartThe American Journal of Medicine, 1971